Abstract
Nipah virus (NiV) is one of the most common viral diseases affecting the brain and nervous system of the body. To date, there is no significant antiviral drug specifically designed to inhibit NiV. In the last ten years, there has been a significant increase in interest in multitarget drug development. Therefore, the reported work focuses on designing a multitarget inhibitor for NiV. Among the twelve designed compounds, five exhibited better drug-likeness and ADMET properties, hence being selected for further analysis. In a molecular docking study, these compounds possessed better binding affinity as compared to Favipiravir. The RMSD of these compounds was ≤2Å and the number of H-bonds signified the better stability of the complexes formed. The ΔGbind of C4, C6 and C7 was found to be comparatively higher than the other screened compounds, revealing their greater ability to bind efficiently with NiV-G, NiV-F and NiV-N receptors, respectively. Therefore, based on molecular docking, molecular dynamics, and MM/PBSA analysis, these compounds can act as potential inhibitors of multitargets of NiV.
Communicated by Ramaswamy H. Sarma
Acknowledgments
Author, Prashasti Sinha is very thankful to the University Grant Commission (UGC), New Delhi, India, for the financial support for doctoral research work. Authors would like to acknowledge IIT Delhi, India for allowing the access to SCFBio web server.
Author contribution
Authors, P.S. and A.K.Y. have contributed equally in the work.
Data availability statement
There is no associated data for this manuscript.
Disclosure statement
No potential conflict of interest was reported by the authors.